Navigation Links
Tobacco company misrepresented danger from cigarettes
Date:1/6/2012

A new UCSF analysis of tobacco industry documents shows that Philip Morris USA manipulated data on the effects of additives in cigarettes, including menthol, obscuring actual toxicity levels and increasing the risk of heart, cancer and other diseases for smokers.

Tobacco industry information can't be taken at face value, the researchers conclude. They say their work provides evidence that hundreds of additives, including menthol, should be eliminated from cigarettes on public health grounds.

The article is published in PLoS Medicine http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001145

In the new, independent study, the scientists reassessed data from Philip Morris' "Project MIX," which detailed chemical analyses of smoke and animal toxicology studies of 333 cigarette additives. Philip Morris, the nation's largest tobacco company, published its findings in 2002.

By investigating the origins and design of Project MIX, the UCSF researchers conducted their own inquiry into the Philip Morris results. They stressed that many of the toxins in cigarette smoke substantially increased after additives were added to cigarettes.

They also found, after obtaining evidence that additives increased toxicity, that tobacco scientists adjusted the protocol for presenting their results in a way that obscured these increases.

"We discovered these post-hoc changes in analytical protocols after the industry scientists found that the additives increased cigarette toxicity by increasing the number of fine particles in the cigarette smoke that cause heart and other diseases," said senior author Stanton A. Glantz, PhD, UCSF professor of medicine and director of the Center for Tobacco Control Research and Education at UCSF.

"When we conducted our own analysis by studying additives per cigarette following Philip Morris' original protocol -- we found that 15 carcinogenic chemicals increased by 20 percent or more," he said.

Additionally, in the independent study, the researchers discovered the reason behind Philip Morris' failure to identify many toxic effects in animal studies: its studies were too small.

"The experiment was too small in terms of the number of rats analyzed to statistically detect important changes in biological effects," Glantz said. "Philip Morris underpowered its own studies."

The results of "Project MIX" were first published as four papers in a 2002 edition of Food and Chemical Toxicology, a journal whose editor and many members of its editorial board had financial ties to the tobacco industry. While Philip Morris was trying to get the papers published, the company scientist who led Project Mix sent an email to a colleague describing the peer review process as "an inside job." http://legacy.library.ucsf.edu/tid/ekw86a00/pdf?search=%22inside%20job%20philip%20morris%20project%20mix%20email%22

In the new study, the researchers used documents made public as a result of litigation against the tobacco industry. The documents are available to the public through UCSF's Legacy Tobacco Documents Library.


'/>"/>
Contact: Elizabeth Fernandez
elizabeth.fernandez@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert  

Related medicine news :

1. New report identifies research needed on modified risk tobacco products
2. UCSF to receive tobacco papers, funding to improve public access to the documents
3. States could see substantial savings with tobacco control programs
4. UIC awarded $14 million to study tobacco pricing and media
5. National Study Will Track Tobacco Use in U.S.
6. FDA and NIH announce joint study on tobacco use and risk perceptions
7. Big Tobacco knew radioactive particles in cigarettes posed cancer risk but kept quiet
8. Stronger tobacco control policy in the Netherlands would save thousands of lives
9. UCSF, UC Merced to study effectiveness of anti-tobacco programs
10. Effects of tobacco use among rural African American young adult males
11. Illegal Tobacco Sales to U.S. Minors Reach All-Time Low
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Tobacco company misrepresented danger from cigarettes
(Date:2/17/2017)... ... 17, 2017 , ... The Alliance Healthcare Foundation (AHF) announced ... positively impact the health and wellness of our community in San Diego and ... to seriously consider releasing our assets beyond our 5% targeted distribution each year ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... brings its educational assistance management solution to the exhibit floor for the ... Orlando, Fla. , From Feb. 19–23, 2017, more than 40,000 healthcare industry ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Dr. Carol Francis' goals for each and every seminar, session and class ... will demonstrate five different brainwave tools which help energize creativity, focus mental functions, ...
(Date:2/17/2017)... WA (PRWEB) , ... February 17, 2017 , ... ... management organizations, has been named a finalist in the 8th Annual DecisionHealth Platinum ... America's healthcare delivery system. Qualis Health’s work is recognized across multiple award categories, ...
(Date:2/17/2017)... ... 17, 2017 , ... Program will serve more than 5,000 ... U.S. Soccer Foundation announced today that they have awarded nine grants to expand ... Foundation’s soccer mentoring program, teaches kids the fundamentals of soccer while striving to ...
Breaking Medicine News(10 mins):
(Date:2/19/2017)... , Feb. 19, 2017  nThrive™, an ... cycle portfolio and thought leadership at the 2017 ... a category leader award from KLAS. ... discussion focused on how market trends shape the ... particularly a sophisticated, comprehensive Patient Access solution. The ...
(Date:2/18/2017)... , Feb. 17, 2017  Pharmaceutical companies have long ... products either in development or already on the market.   ... the pharma industry to alter how it manages advisory board ... leader Best Practices, LLC conducted a new study focused on ... ...
(Date:2/17/2017)... , Feb. 17, 2017 Theravance ... Biopharma" or the "Company") today announced the presentation ... potent, and orally administered pan-Janus kinase (JAK) inhibitor ... th Congress of the European Crohn,s and ... Company reported further data from its completed Phase ...
Breaking Medicine Technology: